Antisynthetase syndrome and pulmonary hypertension: report of two cases and review of the literature

• Published in: Modern rheumatology case reports Vol. 5; no. 1; pp. 152 - 155
• Main Authors: García-Fernández, Antía, Quezada-Loaiza, Carlos Andrés, de la Puente-Bujidos, Carlos
• Format: Journal Article
• Language: English
• Published: England 01-01-2021
• Subjects: Antisynthetase syndrome; pulmonary hypertension; anti-ARS antibodies; myositis; connective tissue diseases
• ISSN: 2472-5625; 2472-5625
• DOI: 10.1080/24725625.2020.1794521

Antisynthetase Syndrome (ASS) is a subset of idiopathic inflammatory myopathies characterised by specific clinical features such as interstitial lung disease (ILD), fever, myositis, Raynaud's phenomenon, cutaneous involvement and arthritis related to the presence of anti-aminoacyl-tRNA-synthetase (anti-ARS) autoantibodies. Moreover, Pulmonary arterial hypertension (PAH) is a life-threatening complication associated with connective tissue diseases mainly systemic sclerosis (SSc-PAH). It has been suggested that PAH can complicate ASS patients but little is known about the prevalence and risk factors to develop this complication. Here we report on two patients with ASS and PH. The first one represents a complete picture of ASS anti-Jo-1 positive, the second an amyophatic ASS anti-PL-12 positive. In one of our ASS-PAH patients, specific treatment lead to improvement of PAH. There are no specific recommendations on current guidelines regarding either PAH screening or treatment in ASS, but performing echocardiogram, ECG, pulmonary function test and prompt initiation of specific therapies seems to improve right heart catheterisation (RHC) parameters and survival.